1. Home
  2. AACB vs NMRA Comparison

AACB vs NMRA Comparison

Compare AACB & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AACB
  • NMRA
  • Stock Information
  • Founded
  • AACB 2024
  • NMRA 2019
  • Country
  • AACB United States
  • NMRA United States
  • Employees
  • AACB N/A
  • NMRA N/A
  • Industry
  • AACB
  • NMRA
  • Sector
  • AACB
  • NMRA
  • Exchange
  • AACB Nasdaq
  • NMRA Nasdaq
  • Market Cap
  • AACB 298.1M
  • NMRA 268.5M
  • IPO Year
  • AACB 2025
  • NMRA 2023
  • Fundamental
  • Price
  • AACB $10.13
  • NMRA $1.63
  • Analyst Decision
  • AACB
  • NMRA Buy
  • Analyst Count
  • AACB 0
  • NMRA 8
  • Target Price
  • AACB N/A
  • NMRA $7.14
  • AVG Volume (30 Days)
  • AACB 230.0
  • NMRA 1.4M
  • Earning Date
  • AACB 01-01-0001
  • NMRA 08-06-2025
  • Dividend Yield
  • AACB N/A
  • NMRA N/A
  • EPS Growth
  • AACB N/A
  • NMRA N/A
  • EPS
  • AACB N/A
  • NMRA N/A
  • Revenue
  • AACB N/A
  • NMRA N/A
  • Revenue This Year
  • AACB N/A
  • NMRA N/A
  • Revenue Next Year
  • AACB N/A
  • NMRA N/A
  • P/E Ratio
  • AACB N/A
  • NMRA N/A
  • Revenue Growth
  • AACB N/A
  • NMRA N/A
  • 52 Week Low
  • AACB $10.00
  • NMRA $0.61
  • 52 Week High
  • AACB $11.35
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • AACB N/A
  • NMRA 52.38
  • Support Level
  • AACB N/A
  • NMRA $1.49
  • Resistance Level
  • AACB N/A
  • NMRA $1.70
  • Average True Range (ATR)
  • AACB 0.00
  • NMRA 0.18
  • MACD
  • AACB 0.00
  • NMRA -0.06
  • Stochastic Oscillator
  • AACB 0.00
  • NMRA 25.00

About AACB Artius II Acquisition Inc. Class A Ordinary Shares

Artius II Acquisition Inc is a blank check company.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: